Greenhaven Road Investment Management, LP on Lifecore Biomedical, Inc.
Thesis
Greenhaven's thesis centers on monetizing Lifecore's excess pharmaceutical manufacturing capacity. The company added seven customers in nine months, including at least two that the fund believes could become significant, although regulatory approvals create a lag before revenue arrives. The strategic-alternatives process provides another path to value realization, particularly because insiders control more than 30% of the company. Greenhaven's analysis suggests a sale could occur at a substantial premium, potentially exceeding 100%, while the existing share price embeds little takeover premium. Contractual minimums and expected customer ramps should also support a return to growth in 2027 with further acceleration in 2028.
“The entire thesis is that they can sell their excess manufacturing capacity.”
Key risks
- FDA approvals can delay customer revenue
- New customer wins may not fully utilize excess capacity
- The strategic review may not result in a sale